Vaccines
RSSArticles
-
COVID-19 Infection More Likely to Inflame Heart Than Vaccine
Researchers noted patients were much more likely to be afflicted with myocarditis after a SARS-CoV-2 infection than after receiving a vaccine.
-
Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373)
Novavax is authorized to be administered to patients age 18 years and older for active immunization to prevent COVID-19 caused by SARS-CoV-2.
-
Text Messages Boosted Pediatric Flu Vaccination Rates
Personalized, interactive, educational reminders led parents to bring children for the second shot faster and at a higher rate.
-
Clinician: Vaccinate Children to Prevent Long COVID
With public health officials recently recommending vaccinating children as young as 6 months of age for COVID-19, a clinician voiced a passionate plea to immunize this vulnerable population to prevent severe outcomes and death.
-
A Shot in the Dark: FDA Adding Omicron to New Fall Vaccine
With the Omicron BA.5 subvariant currently the dominant strain of COVID-19 in the United States, vaccine experts have decided to add some component of the rapidly mutating virus to a new bivalent booster that will be rolled out this fall.
-
Monkeypox Spread to 29 Non-Endemic Nations Unprecedented
The near-simultaneous emergence of monkeypox in the United States, Europe, and other regions where it rarely is seen has raised questions whether the virus could become endemic beyond West and Central Africa, where it is common.
-
Who Can Receive the Non-mRNA COVID-19 Vaccine Now?
The FDA recently limited the use of the Janssen COVID-19 vaccine.
-
Two-Dose Novavax Added to List of U.S. COVID-19 Vaccines
The FDA issued an emergency use authorization for the fourth vaccine.
-
HPV Vaccination Rate Needs Improvement
The prevalence of HPV infections and their sequelae remain high, although this is a problem that is preventable with available vaccines.
-
HPV Vaccination in Adolescence Prevents Cancer More than 10 Years Later
In a study of human papillomavirus (HPV) vaccination, researchers evaluated cancer protection over up to 11 years of follow-up. During this time, the authors noted 100% vaccine efficacy at preventing HPV-associated cancers.